Autor:	Jason B Douglas, Swetha Chenna, Venu Madhav Chippa, Matthew R Fulton, Amr Moussa, Amy R Hurst
Rok vydání:	2018
Předmět:	medicine.medical_specialty Rivaroxaban business.industry Atrial fibrillation General Medicine medicine.disease Subcapsular Hematoma Internal medicine Stroke prevention cardiovascular system medicine Cardiology cardiovascular diseases business medicine.drug
Zdroj:	Archives of Hematology Case Reports and Reviews. :004-006
ISSN:	2640-7914
DOI:	10.17352/ahcrr.000012
Popis:	Rivaroxaban was approved for stroke prevention for non-valvular atrial fibrillation in 2011, with added advantage of decreased risk of bleeding in comparison to coumadin, made it a good alternative for coumadin.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::23b9683e8cc0de8906d181b0c9712e5e https://doi.org/10.17352/ahcrr.000012 Zobrazit plný text záznamu